Find NINDS Clinical Trials

Study Title	Location	Status	Disorders
A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients	Maryland	Completed	Multiple Sclerosis
A Comparison of an Implanted Neuroprosthesis With Sensory Training for Improving Airway Protection in Chronic Dysphagia	Maryland*	Completed	Chronic Dysphagia, Multiple Sclerosis, Parkinson Disease
Assessment of Patients With Multiple Sclerosis (MS)	Maryland*	Completed	Herpesviridae Infection, HTLV-I Infection, Multiple Sclerosis, Tropical Spastic Paraparesis, Vasculitis
Biomarkers in Multiple Sclerosis	Maryland*	Completed	Multiple Sclerosis
Brain Peripheral Benzodiazepine Receptors in Patients With Multiple Sclerosis	Maryland*	Completed	Multiple Sclerosis
Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System	Maryland*	Recruiting	Central Nervous System Disease, Multiple Sclerosis
Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)	Maryland*	Terminated	Multiple Sclerosis
Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques	Canada	Enrolling by Invitation	Multiple Sclerosis
Effects of Stimulation Patterns of Deep Brain Stimulation	Multiple U.S. Locations	Enrolling by Invitation	Parkinson Disease, Essential Tremor, Multiple Sclerosis
Idebenone for Primary Progressive Multiple Sclerosis	Maryland*	Enrolling by Invitation	Multiple Sclerosis, Primary Progressive Multiple Sclerosis